Beyfortus™—
Now ACIP Recommended!
View press release

Get Updates

For Your Practice

Sanofi is here to help support your patients, their families, and caregivers.

For more information regarding Beyfortus and to receive future updates, call 1-855-BEYFORTUS  (1-855-239-3678)
or connect with us through the following options.

Reminder: This feature is intended for US healthcare professionals only.
Please fill in the required fields below.

*Required fields

How would you like to receive information about Beyfortus? (Choose all that apply.)*
What information are you interested in learning more about? (Choose all that apply.)
Would you like to receive future text messages about Beyfortus updates?

By submitting the following information, you are acknowledging that you understand that the information you provide may be used by Sanofi and their affiliates, and the business service companies working with Sanofi, to provide you with additional communications and to develop products and services, which may include market research.

Sanofi respects your interest in keeping your personal health information private. We will not sell or rent your information to any third parties or outside mailing lists.

You may have certain rights under applicable data privacy laws regarding the personal information that you provide to Sanofi, including the right to access your personal information held by Sanofi. For further information regarding these rights, please reference our Global Privacy Policy.

IMPORTANT SAFETY INFORMATION
Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

  • Hypersensitivity Including Anaphylaxis: Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human IgG1 monoclonal antibodies. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.

  • Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Please see full Prescribing Information.

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

INDICATION

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
IMPORTANT SAFETY INFORMATION
Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions
INDICATION

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
INDICATION

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in: